Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer

Abstract

This phase II study evaluated the activity of gemcitabine (Gemzar) plus cisplatin (Platinol) as first-line treatment of advanced epithelial ovarian cancer. Forty-two chemonaive patients with advanced (stage III and IV) epithelial ovarian cancer received gemcitabine 1250 mg/m2 on days 1 and 8 and cisplatin 100 mg/m2 on day 1, every 3 weeks, up to eight cycles. The median number of cycles completed was 5 (range 2–8). Of the 41 patients evaluable for tumor response, 20 had a partial response and nine had a complete response, for an overall clinical and pathologic response rate of 70.7% (95% CI 56.8–84.6%). Median overall survival for all 42 patients was 23.4 months (95% CI 15.9–29.9 months) and the median progression-free survival time was 10.4 months (95% CI 9.4–13.5 months). The combination was generally manageable. Hematologic toxicity (grade 3/4 neutropenia: 31.0/21.4%; grade 3/4 thrombocytopenia: 9.5/4.8%; grade 3/4 anemia: 11.9/0%) and nausea and vomiting (grade 3/4: 35.7/31.0%) were the most common toxicities. There was one toxic death (septic shock due to hematologic toxicity-induced infection). We conclude that gemcitabine plus cisplatin is active and feasible as first-line treatment of advanced epithelial ovarian cancer. Further clinical trials with the addition of gemcitabine to first-line treatment appear warranted.